{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:52:39Z","timestamp":1791924759976,"version":"4.3.4"},"reference-count":33,"publisher":"Spandidos Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol Clin Oncol"],"DOI":"10.3892\/mco.2020.2042","type":"journal-article","created":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T12:21:56Z","timestamp":1588681316000},"page":"38-42","source":"Crossref","is-referenced-by-count":15,"title":["Guillain\u2011Barre syndrome induced by pembrolizumab and sunitinib: A case report"],"prefix":"10.3892","volume":"13","author":[{"given":"Chen","family":"Han","sequence":"first","affiliation":[{"name":"Department of Oncology, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin\u2011An","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuna","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhong","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanqiang","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2020,5,5]]},"reference":[{"key":"key20200713202848_b1-mco-0-0-2042","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1212\/CON.0000000000000513","article-title":"Guillain-barr\u00e9 syndrome","volume":"92","author":"Wijdicks","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"key20200713202848_b2-mco-0-0-2042","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1177\/1060028015586218","article-title":"Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology","volume":"49","author":"Barbee","year":"2015","journal-title":"Ann Pharmacother"},{"key":"key20200713202848_b3-mco-0-0-2042","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in Advanced Melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"key20200713202848_b4-mco-0-0-2042","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"key20200713202848_b5-mco-0-0-2042","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S1470-2045(16)30066-3","article-title":"Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): An open-label, multicentre, phase 1B trial","volume":"17","author":"Seiwert","year":"2016","journal-title":"Lancet Oncol"},{"key":"key20200713202848_b6-mco-0-0-2042","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"key20200713202848_b7-mco-0-0-2042","doi-asserted-by":"publisher","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"ESMO Guidelines Committee: Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28 (suppl 4)","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"key20200713202848_b8-mco-0-0-2042","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"key20200713202848_b9-mco-0-0-2042","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/nrneurol.2014.121","article-title":"Guillain-Barre syndrome: Pathogenesis, diagnosis, treatment and prognosis","volume":"10","author":"van den Berg","year":"2014","journal-title":"Nat Rev Neurol"},{"key":"key20200713202848_b10-mco-0-0-2042","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/imr.12170","article-title":"Regulatory T-cell homeostasis: Steady-state maintenance and modulation during inflammation","volume":"259","author":"Smigiel","year":"2014","journal-title":"Immunol Rev"},{"key":"key20200713202848_b11-mco-0-0-2042","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jaut.2018.08.007","article-title":"A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity","volume":"95","author":"Kumar","year":"2018","journal-title":"J Autoimmun"},{"key":"key20200713202848_b12-mco-0-0-2042","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.4049\/jimmunol.1402695","article-title":"Regulatory T cells in melanoma revisited by a computational clustering of FOXP3+ T cell subpopulations","volume":"196","author":"Fujii","year":"2016","journal-title":"J Immunol"},{"key":"key20200713202848_b13-mco-0-0-2042","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1158\/0008-5472.CAN-04-3232","article-title":"Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma","volume":"65","author":"Ormandy","year":"2005","journal-title":"Cancer Res"},{"key":"key20200713202848_b14-mco-0-0-2042","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.lungcan.2011.06.002","article-title":"Prognostic potential of FOXP3 expression in non-small cell lung cancer cells combined with tumor-infiltrating regulatory T cells","volume":"75","author":"Tao","year":"2012","journal-title":"Lung Cancer"},{"key":"key20200713202848_b15-mco-0-0-2042","doi-asserted-by":"publisher","first-page":"33159","DOI":"10.18632\/oncotarget.16565","article-title":"Preferential accumulation of regulatory T cells with highly immunosuppressive characteristics in breast tumor microenvironment","volume":"8","author":"Syed Khaja","year":"2017","journal-title":"Oncotarget"},{"key":"key20200713202848_b16-mco-0-0-2042","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1093\/intimm\/dxw025","article-title":"Roles of regulatory T cells in cancer immunity","volume":"28","author":"Takeuchi","year":"2016","journal-title":"Int Immunol"},{"key":"key20200713202848_b17-mco-0-0-2042","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J"},{"key":"key20200713202848_b18-mco-0-0-2042","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1056\/NEJMoa1611406","article-title":"Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy","volume":"375","author":"Ravaud","year":"2016","journal-title":"N Engl J Med"},{"issue":"pii: E461","key":"key20200713202848_b19-mco-0-0-2042","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18020461","article-title":"Effects and side effects of using sorafenib and sunitinib in the treatment of metastatic renal cell carcinoma","volume":"18","author":"Randrup Hansen","year":"2017","journal-title":"Int J Mol Sci"},{"key":"key20200713202848_b20-mco-0-0-2042","first-page":"66","article-title":"Guillain-Barre syndrome after treatment with sunitinib malate?","volume":"22","author":"Mulherin","year":"2008","journal-title":"Oncology (Williston Park)"},{"issue":"712040","key":"key20200713202848_b21-mco-0-0-2042","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/712040","article-title":"Guillain-barre syndrome following treatment with sunitinib malate","volume":"2014","author":"Kanaan","year":"2014","journal-title":"Case Rep Oncol Med"},{"key":"key20200713202848_b22-mco-0-0-2042","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1158\/1535-7163.MCT-10-1124","article-title":"New insights into molecular mechanisms of sunitinib-associated side effects","volume":"10","author":"Aparicio-Gallego","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"key20200713202848_b23-mco-0-0-2042","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1136\/jnnp-2017-316510","article-title":"Acute demyelinating polyneuropathy induced by nivolumab","volume":"89","author":"Fukumoto","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key20200713202848_b24-mco-0-0-2042","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jocn.2017.07.014","article-title":"Immune mediated neuropathy following checkpoint immunotherapy","volume":"45","author":"Gu","year":"2017","journal-title":"J Clin Neurosci"},{"key":"key20200713202848_b25-mco-0-0-2042","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1007\/s00432-016-2191-7","article-title":"A case of fatal Guillain-Barre syndrome from anti-PD1 monoclonal antibody use","volume":"142","author":"Jacob","year":"2016","journal-title":"J Cancer Res Clin"},{"key":"key20200713202848_b26-mco-0-0-2042","doi-asserted-by":"publisher","first-page":"e360","DOI":"10.1016\/j.clgc.2018.11.022","article-title":"Guillain-barre syndrome related to nivolumab: Case report of a patient with urothelial cancer and review of the literature","volume":"17","author":"Kyriazoglou","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"key20200713202848_b27-mco-0-0-2042","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jns.2018.04.028","article-title":"Nivolumab-induced acute demyelinating polyradiculoneuropathy mimicking Guillain-Barre syndrome","volume":"390","author":"Nukui","year":"2018","journal-title":"J Neurol Sci"},{"key":"key20200713202848_b28-mco-0-0-2042","doi-asserted-by":"publisher","first-page":"395","DOI":"10.2340\/00015555-2548","article-title":"PD-1 antibody-induced guillain-barre syndrome in a patient with metastatic melanoma","volume":"97","author":"Schneiderbauer","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"key20200713202848_b29-mco-0-0-2042","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1097\/CND.0000000000000193","article-title":"Guillain-barre syndrome triggered by immune checkpoint inhibitors: A case report and literature review","volume":"19","author":"Supakornnumporn","year":"2017","journal-title":"J Clin Neuromuscul"},{"key":"key20200713202848_b30-mco-0-0-2042","doi-asserted-by":"publisher","first-page":"e761","DOI":"10.1097\/MJT.0000000000000771","article-title":"Nivolumab-associated Guillain-barre syndrome in a patient with non-small-cell lung cancer","volume":"25","author":"Thapa","year":"2018","journal-title":"Am J Ther"},{"key":"key20200713202848_b31-mco-0-0-2042","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1056\/NEJMc1515584","article-title":"Pembrolizumab-induced demyelinating polyradiculoneuropathy","volume":"375","author":"de Maleissye","year":"2016","journal-title":"N Engl J Med"},{"issue":"e3371","key":"key20200713202848_b32-mco-0-0-2042","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.3371","article-title":"Case reports of pembrolizumab-induced acute inflammatory demyelinating polyneuropathy","volume":"10","author":"Manam","year":"2018","journal-title":"Cureus"},{"key":"key20200713202848_b33-mco-0-0-2042","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1002\/mus.26101","article-title":"Guillain-Barre-like syndrome during pembrolizumab treatment","volume":"58","author":"Ong","year":"2018","journal-title":"Muscle Nerve"}],"container-title":["Molecular and Clinical Oncology"],"original-title":[],"deposited":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T19:43:53Z","timestamp":1597261433000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/mco.2020.2042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,5]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,5,5]]}},"URL":"https:\/\/doi.org\/10.3892\/mco.2020.2042","relation":{},"ISSN":["2049-9450","2049-9469"],"issn-type":[{"value":"2049-9450","type":"print"},{"value":"2049-9469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,5]]}}}